Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials-Reference-Cited by-同舟云学术

Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials

Published:2022-07-14 Issue:11 Volume:33 Page:2297-2305
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Lorentzon Mattias^ORCID,Johansson Helena,Harvey Nicholas C.,Liu Enwu,Vandenput Liesbeth,Crandall Carolyn J.,Cauley Jane A.,LeBoff Meryl S.,McCloskey Eugene V.,Kanis John A.

Funder

University of Gothenburg

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00198-022-06483-y.pdf

Reference37 articles.

1. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

2. Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712

3. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738